Tag #Vaccine Research

Showing 1 to 4 of 4 results

cbsnews.com

🌐 85% Global Worthiness

Sep 9, 04:20

Former Top NIH Official Alleges Retaliation, Clashes over Vaccine Research

Dr. Jeanne Marrazzo, former head of NIH's NIAID, alleges retaliation after opposing Trump administration efforts to curtail vaccine research, citing dangers to public health.

Former Top NIH Official Alleges Retaliation, Clashes over Vaccine Research

Dr. Jeanne Marrazzo, former head of NIH's NIAID, alleges retaliation after opposing Trump administration efforts to curtail vaccine research, citing dangers to public health.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did Dr. Marrazzo's attempts to oppose these actions unfold, and what was the outcome?

Marrazzo "raised concerns" to agency leadership but was ultimately disregarded. She and her colleagues felt "like we were sort of a voice in the wilderness." After filing a whistleblower complaint, she was placed on leave and reassigned to the Indian Health Service in April 2024, despite having only been in her position since August 2023.

bbc.com

🌐 85% Global Worthiness

Aug 9, 13:16

US Cuts Funding for mRNA Vaccine Research Amidst Pandemic Preparedness Debate

The U.S. ended funding for \$500 million in mRNA vaccine research, sparking debate over its potential impact on future pandemics, as mRNA vaccines proved effective during Covid-19 but face challenges in protecting against evolving viruses.

US Cuts Funding for mRNA Vaccine Research Amidst Pandemic Preparedness Debate

The U.S. ended funding for \$500 million in mRNA vaccine research, sparking debate over its potential impact on future pandemics, as mRNA vaccines proved effective during Covid-19 but face challenges in protecting against evolving viruses.

Progress

60% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate implications of the U.S. government's decision to cut funding for mRNA vaccine research, considering the technology's proven efficacy and potential future applications?

The U.S. ended funding for 22 mRNA vaccine projects, totaling \$500 million. This decision is controversial, with some experts calling it a reckless mistake given mRNA vaccines' life-saving role during the COVID-19 pandemic and their potential for future pandemics. Others argue that the technology has limitations and that funding should shift to more broadly effective approaches.

cbsnews.com

🌐 85% Global Worthiness

Sep 7, 22:18

Kennedy's HHS Actions Spark Physician's Plea for Senate Oversight

Following Robert F. Kennedy Jr.'s firing of CDC officials and cuts to mRNA vaccine research, a physician urges Senator Bill Cassidy to fulfill his promise of HHS oversight.

Kennedy's HHS Actions Spark Physician's Plea for Senate Oversight

Following Robert F. Kennedy Jr.'s firing of CDC officials and cuts to mRNA vaccine research, a physician urges Senator Bill Cassidy to fulfill his promise of HHS oversight.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the stated justifications for these actions, and how do they compare to expert opinions?

Kennedy stated that HHS determined mRNA technology poses more risks than benefits for respiratory viruses. However, vaccine experts strongly disagree, citing the technology's effectiveness against COVID-19 and its potential for future life-saving applications, including cancer treatments. The funding cuts have been described as "one of the worst decisions" in decades of public health work.

cnnespanol.cnn.com

🌐 85% Global Worthiness

Mar 30, 04:11

NIH Cancels $2 Million Vaccine Safety Grant Amidst Policy Shift

Dr. Nisha Acharya's nearly $2 million NIH grant to study the Shingrix vaccine's safety and efficacy was canceled on March 10th due to a new HHS policy shift under Robert F. Kennedy Jr.'s leadership, impacting her research team and highlighting concerns about research funding.

NIH Cancels $2 Million Vaccine Safety Grant Amidst Policy Shift

Dr. Nisha Acharya's nearly $2 million NIH grant to study the Shingrix vaccine's safety and efficacy was canceled on March 10th due to a new HHS policy shift under Robert F. Kennedy Jr.'s leadership, impacting her research team and highlighting concerns about research funding.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the NIH's policy change on research related to vaccine safety and efficacy, particularly concerning the Shingrix vaccine?

On March 10, Dr. Nisha Acharya's NIH grant to study the safety and efficacy of the Shingrix vaccine was canceled due to a policy shift under the new HHS leadership. The cancellation impacts nearly $2 million in funding and three full-time employees. Dr. Acharya maintains her patient care responsibilities but loses approximately 35% of her salary.

Showing 1 to 4 of 4 results